Enveric Biosciences (ENVB)
(Delayed Data from NSDQ)
$0.90 USD
-0.01 (-0.56%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $0.91 +0.02 (1.68%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth C Momentum F VGM
Income Statements
Fiscal Year end for Enveric Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 40 |
Cost Of Goods | 0 | 0 | 0 | 0 | 32 |
Gross Profit | 0 | 0 | 0 | 0 | 8 |
Selling & Adminstrative & Depr. & Amort Expenses | 16 | 27 | 65 | 6 | 14 |
Income After Depreciation & Amortization | -16 | -27 | -65 | -6 | -6 |
Non-Operating Income | -1 | 7 | 8 | -1 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 1 |
Pretax Income | -17 | -20 | -56 | -7 | -5 |
Income Taxes | 0 | -1 | -7 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -17 | -18 | -49 | -7 | -6 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -17 | -18 | -49 | -7 | -6 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -16 | -20 | -25 | -5 | -4 |
Depreciation & Amortization (Cash Flow) | 0 | 8 | 39 | 0 | 2 |
Income After Depreciation & Amortization | -16 | -27 | -65 | -6 | -6 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 2.16 | 1.45 | 0.47 | 0.12 | 0.01 |
Diluted EPS Before Non-Recurring Items | -8.01 | -8.86 | -21.50 | -59.50 | -566.00 |
Diluted Net EPS (GAAP) | -8.09 | -13.00 | -103.50 | -59.50 | -566.00 |
Fiscal Year end for Enveric Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 2.38 | 3.45 | 5.76 | 4.86 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -2.38 | -3.45 | -5.76 | -4.86 |
Non-Operating Income | NA | -1.03 | 0.63 | -0.60 | 0.18 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -3.41 | -2.82 | -6.36 | -4.68 |
Income Taxes | NA | 0.04 | -0.01 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -3.45 | -2.81 | -6.36 | -4.68 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -3.44 | -2.82 | -6.36 | -4.68 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 2.35 | 2.17 | 2.11 | 2.08 |
Diluted EPS Before Non-Recurring Items | NA | -1.46 | -1.30 | -3.04 | -2.22 |
Diluted Net EPS (GAAP) | NA | -1.44 | -1.30 | -3.04 | -2.31 |